INOVIO PHARMACEUTICALS, INC.: directors' dealings · United States · SEC (Form 4)

About INOVIO PHARMACEUTICALS, INC.

INOVIO PHARMACEUTICALS, INC. (ticker: INO) is a U.S.-listed biotechnology company trading on NASDAQ in the United States, with corporate headquarters in Plymouth Meeting, Pennsylvania. INOVIO is focused on developing and commercializing DNA medicines, a differentiated platform designed to help the body produce therapeutic proteins through engineered DNA plasmids delivered by the company’s proprietary CELLECTRA devices. For international equity investors, this is best viewed as a clinical-stage biotech story with meaningful scientific optionality, but also high dependence on trial data, regulatory decisions, and financing execution. ([ir.inovio.com](https://ir.inovio.com/overview/default.aspx?utm_source=openai)) Founded in 1983, INOVIO has spent decades building a platform around DNA medicine design and electroporation-based delivery. The company’s historical and current focus spans HPV-related diseases, cancer, and infectious diseases. Its pipeline includes multiple clinical and preclinical programs, but the clear lead asset is INO-3107, being developed for recurrent respiratory papillomatosis (RRP), a rare HPV-related disease of the respiratory tract that often requires repeated surgeries. INOVIO has said INO-3107 could become its first commercial product and potentially the first DNA medicine approved in the United States. ([ir.inovio.com](https://ir.inovio.com/news/news-details/2025/INOVIO-Completes-Rolling-BLA-Submission-Seeking-Accelerated-Approval-for-INO-3107-as-a-Treatment-for-RRP-in-Adults/default.aspx?utm_source=openai)) From a competitive standpoint, INOVIO occupies a niche position within biotech. Its main differentiator is a proprietary DNA medicines platform that uses plasmid design plus a delivery device rather than viral vectors or lipid nanoparticles. That gives the company a distinct scientific narrative and a potentially broad technology base, but the investment case remains binary in many respects: platform value will be judged by whether the lead program can achieve regulatory success and whether the company can convert its science into commercial execution. The company also highlights partnerships and collaborations, which can help offset development cost and expand credibility. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1055726/000105572625000026/ino-20250331.htm?utm_source=openai)) Geographically, INOVIO remains heavily U.S.-centric. Its headquarters are in Pennsylvania, its 2025 revenue was earned entirely in the United States, and all of its long-lived assets are located in the U.S. That profile underscores a domestic operating base, even though the company’s disease targets and eventual commercial opportunities may have global relevance. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1055726/000105572626000008/ino-20251231.htm?utm_source=openai)) The most important recent development is regulatory: in December 2025, the FDA accepted the Biologics License Application for INO-3107 for review under the accelerated approval pathway and assigned a PDUFA target date of October 30, 2026. In April 2026, INOVIO said the FDA’s mid-cycle review did not raise new major issues, while also noting that the agency had preliminarily questioned eligibility for accelerated approval. For investors, this is the key near-term catalyst and the main event to watch, because it could determine whether INOVIO transitions from a development-stage company into a commercial-stage one. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1055726/000105572626000018/ino-20260331.htm?utm_source=openai))